Cargando…
A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy
We present a 74-year-old male with nonspecific interstitial pneumonia (NSIP) during treatment with ibrutinib for mantle cell lymphoma. Previously, the patient had received six cycles of bendamustine and rituximab and six cycles of R-CHOP, followed by rituximab maintenance therapy. Respiratory tract...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702410/ https://www.ncbi.nlm.nih.gov/pubmed/29259834 http://dx.doi.org/10.1155/2017/5640186 |
_version_ | 1783281523850477568 |
---|---|
author | Jungmann, Sven Ludwig, Wolf-Dieter Schönfeld, Nicolas Blum, Torsten-Gerriet Großwendt, Claudia Boch, Christian Rehbock, Beate Griff, Sergej Schmittel, Alexander Bauer, Torsten T. |
author_facet | Jungmann, Sven Ludwig, Wolf-Dieter Schönfeld, Nicolas Blum, Torsten-Gerriet Großwendt, Claudia Boch, Christian Rehbock, Beate Griff, Sergej Schmittel, Alexander Bauer, Torsten T. |
author_sort | Jungmann, Sven |
collection | PubMed |
description | We present a 74-year-old male with nonspecific interstitial pneumonia (NSIP) during treatment with ibrutinib for mantle cell lymphoma. Previously, the patient had received six cycles of bendamustine and rituximab and six cycles of R-CHOP, followed by rituximab maintenance therapy. Respiratory tract complications of ibrutinib other than infectious pneumonia have not been mentioned in larger trials, but individual case reports hinted to a possible association with the development of pneumonitis. In our patient, the onset of alveolitis that progressed towards NSIP together with the onset of ibrutinib treatment suggests causality. One week after ibrutinib was discontinued, nasal symptoms resolved first. A follow-up CT showed a reduction in the reticular hyperdensities and ground-glass opacities, suggestive of restitution of the lung disease. To our knowledge, this is the first case showing a strong link between ibrutinib and interstitial lung disease, strengthening a previous report on subacute pneumonitis. Our findings have clinical implications because pulmonary side effects were reversible at this early stage. We, therefore, suggest close monitoring for respiratory side effects in patients receiving ibrutinib. |
format | Online Article Text |
id | pubmed-5702410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-57024102017-12-19 A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy Jungmann, Sven Ludwig, Wolf-Dieter Schönfeld, Nicolas Blum, Torsten-Gerriet Großwendt, Claudia Boch, Christian Rehbock, Beate Griff, Sergej Schmittel, Alexander Bauer, Torsten T. Case Rep Oncol Med Case Report We present a 74-year-old male with nonspecific interstitial pneumonia (NSIP) during treatment with ibrutinib for mantle cell lymphoma. Previously, the patient had received six cycles of bendamustine and rituximab and six cycles of R-CHOP, followed by rituximab maintenance therapy. Respiratory tract complications of ibrutinib other than infectious pneumonia have not been mentioned in larger trials, but individual case reports hinted to a possible association with the development of pneumonitis. In our patient, the onset of alveolitis that progressed towards NSIP together with the onset of ibrutinib treatment suggests causality. One week after ibrutinib was discontinued, nasal symptoms resolved first. A follow-up CT showed a reduction in the reticular hyperdensities and ground-glass opacities, suggestive of restitution of the lung disease. To our knowledge, this is the first case showing a strong link between ibrutinib and interstitial lung disease, strengthening a previous report on subacute pneumonitis. Our findings have clinical implications because pulmonary side effects were reversible at this early stage. We, therefore, suggest close monitoring for respiratory side effects in patients receiving ibrutinib. Hindawi 2017 2017-11-10 /pmc/articles/PMC5702410/ /pubmed/29259834 http://dx.doi.org/10.1155/2017/5640186 Text en Copyright © 2017 Sven Jungmann et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Jungmann, Sven Ludwig, Wolf-Dieter Schönfeld, Nicolas Blum, Torsten-Gerriet Großwendt, Claudia Boch, Christian Rehbock, Beate Griff, Sergej Schmittel, Alexander Bauer, Torsten T. A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy |
title | A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy |
title_full | A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy |
title_fullStr | A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy |
title_full_unstemmed | A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy |
title_short | A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy |
title_sort | patient with non-hodgkin lymphoma and nonspecific interstitial pneumonia during ibrutinib therapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702410/ https://www.ncbi.nlm.nih.gov/pubmed/29259834 http://dx.doi.org/10.1155/2017/5640186 |
work_keys_str_mv | AT jungmannsven apatientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT ludwigwolfdieter apatientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT schonfeldnicolas apatientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT blumtorstengerriet apatientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT großwendtclaudia apatientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT bochchristian apatientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT rehbockbeate apatientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT griffsergej apatientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT schmittelalexander apatientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT bauertorstent apatientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT jungmannsven patientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT ludwigwolfdieter patientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT schonfeldnicolas patientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT blumtorstengerriet patientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT großwendtclaudia patientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT bochchristian patientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT rehbockbeate patientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT griffsergej patientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT schmittelalexander patientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy AT bauertorstent patientwithnonhodgkinlymphomaandnonspecificinterstitialpneumoniaduringibrutinibtherapy |